Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Benzene | HCID 241 | — |
| Reactant | Pyrrolidine | HCID 31268 | — |
| Reactant | 5-fluoro-1,3-dihydro-2H-indol-2-one | HCID 3731012 | — |
| Reactant | N-(2-(diethylamino)ethyl)-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide | HCID 20761785 | — |
| Solvent | Toluene | HCID 1140 | — |
| Product | Sunitinib | HCID 5329102 | — |
Reaction Steps
Accordingly, the present invention provides the crystalline Form-C obtained in non-polar alicyclic hydrocarbon solvent like cyclopentane, cyclohexane or cycloheptane. According to the process of the present invention, 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)-amide (IX) and 5-Fluoro-1,3-dihydro-indol-2-one (X) in aromatic hydrocarbon solvents like benzene or toluene are reacted in presence of catalytic amount of pyrrolidine as base at 80-85° C. for 3-9 hours. The resultant Sunitinib base is again triturated with the same solvent at 80-85° C. for 1-2 hours and isolated at a temperature ranging from 20-45° C., preferably at 25-35° and most preferably at 25-30° C. and dried at 60° C. for 5-20 hours to get Sunitinib base (I) as orange crystalline solid.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08466190B2 |
|---|
| Source dataset | uspto-grants-2013_06 |
|---|
| ORD ID | ord-825ebcbe35044aefa31087da6137667d |
|---|
| Source note | uspto-grants-2013_06 |
|---|